Fundz

Athos Therapeutics reported raising $10.3 Million in an initial SEC Form D filing, from an offering of $20 Million

PRIVATEMay 15, 2026$10.3M of $20M raised

Amount Raised

$10.3 Million

$10.3 Million sold, per SEC Form D (first sale Apr 17, 2026)

Round Type

Venture

TorranceBiotechnologyHealthcareHealth CareScience And Engineering

Who to call at Athos Therapeutics, Inc., and when

A new round usually means Athos Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Athos Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Athos Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Athos Therapeutics, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Athos Therapeutics, Inc.

Location

11301 OLYMPIC BLVD., SUITE 592

Torrance, California, United States

About

Athos Therapeutics Inc. is a late-stage preclinical biotech company developing small molecule therapeutics for immune-mediated diseases and cancer using artificial intelligence-generated innovative chemistry and computational platforms. The co-founders of Athos include one of the founders of Kite Pharma (acquired for $12B), the medicinal chemist behind two multi-billion-dollar FDA-approved drugs (Xtandi & Erleada), and the discoverer of the miR-124 drug target, currently in a Phase III IBD trial. Athos identifies novel drug targets (hubs) by integrating clinical and molecular datasets into the biological network of a disease (the disease interactome) and matches them to its small molecule computational chemistry platform. ATH-63, the Company's lead drug compound, is moving into a Phase Ia human clinical early in 2022. The Athos pipeline includes small molecule approaches for various autoimmune disease and cancer.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Athos Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsDimitrios I., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Athos Therapeutics, Inc.'s next move

See what Strategic adds

Athos Therapeutics, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.